Literature DB >> 33754055

Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy.

Liang Zou1,2, Xiaowei Liu3, Jingjing Li2,4, Wei Li3, Lele Zhang3, Chaomei Fu2, Jinming Zhang2, Zhongwei Gu5.   

Abstract

Rationale: Combinations of two or more therapeutic agents targeting different signaling pathways involved in tumor progression can have synergistic anticancer effects. However, combination chemotherapies are greatly limited by the different pharmacokinetics, tumor targeting, and cellular uptake capacities of the combined drugs. We have previously demonstrated the potential synergistic efficacy of paclitaxel (PTX) and the natural anti-angiogenic agent tetramethylpyrazine (TMP) for suppressing ovarian carcinoma growth. An efficient, facile, and smart nanosystem to deliver PTX and TMP simultaneously in vivo is greatly desired.
Methods: We constructed a redox-sensitive nanosystem based on the amphiphilic PTX-ss-TMP conjugate, in which PTX and TMP are linked by a disulfide bond. We characterized the structure of the drug conjugate by 1H NMR and LC-MS, and then prepared PTX-ss-TMP NPs by a one-step nanoprecipitation method. We investigated the redox sensitivity, tumor-targeting ability, anticancer efficacy, and anti-angiogenesis activity of PTX-ss-TMP NPs in vitro and in vivo.
Results: The amphiphilic PTX-ss-TMP conjugate readily self-assembled into stable nanoparticles in aqueous solution with a low critical association concentration of 1.35 µg/mL, well-defined spherical structure, small particle size (152 nm), high drug loading, redox-responsive drug release, high biocompatibility, and high storage stability. In cancer cells pretreated with GSH-OEt, PTX-ss-TMP NPs exhibited higher cytotoxicity, apoptosis rate, and cell-cycle arrest than monotherapy or combination therapy with free drugs, which was attributed to their improved cellular uptake and rapid intracellular drug release. Additionally, PTX-ss-TMP NPs also had a stronger anti-angiogenesis effect in HUVECs than free drug, which was mediated by VEGFR2-involved downstream signals. Finally, PTX-ss-TMP NPs showed tumor-specific accumulation and excellent antitumor activity in A2780 xenograft mice compared with free drug. Conclusions: These in vitro and in vivo results provide clear evidence that this redox-responsive carrier-free nanosystem with intrinsic amphiphilicity has great potential for combination cancer chemotherapy. © The author(s).

Entities:  

Keywords:  combination chemotherapy; disulfide linkage; drug conjugate; paclitaxel; self-assembly.; tetramethylpyrazine

Mesh:

Substances:

Year:  2021        PMID: 33754055      PMCID: PMC7977472          DOI: 10.7150/thno.42260

Source DB:  PubMed          Journal:  Theranostics        ISSN: 1838-7640            Impact factor:   11.556


  37 in total

1.  Nanotechnology in drug delivery and tissue engineering: from discovery to applications.

Authors:  Jinjun Shi; Alexander R Votruba; Omid C Farokhzad; Robert Langer
Journal:  Nano Lett       Date:  2010-09-08       Impact factor: 11.189

2.  Characterization and carboplatin loaded chitosan nanoparticles for the chemotherapy against breast cancer in vitro studies.

Authors:  Md Asad Khan; Md Zafaryab; Syed Hassan Mehdi; Javed Quadri; M Moshahid A Rizvi
Journal:  Int J Biol Macromol       Date:  2017-01-09       Impact factor: 6.953

3.  Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles.

Authors:  Gijung Kwak; Sung Duk Jo; Dongkyu Kim; Hyosuk Kim; Myung Goo Kim; Kwangmeyung Kim; Ick Chan Kwon; Sun Hwa Kim
Journal:  J Control Release       Date:  2017-08-16       Impact factor: 9.776

Review 4.  Advances in combination therapy of lung cancer: Rationales, delivery technologies and dosage regimens.

Authors:  Lan Wu; Donglei Leng; Dongmei Cun; Camilla Foged; Mingshi Yang
Journal:  J Control Release       Date:  2017-05-17       Impact factor: 9.776

Review 5.  Nanomedicine: current status and future prospects.

Authors:  S Moein Moghimi; A Christy Hunter; J Clifford Murray
Journal:  FASEB J       Date:  2005-03       Impact factor: 5.191

6.  Disulfide-cross-linked PEG-poly(amino acid)s copolymer micelles for glutathione-mediated intracellular drug delivery.

Authors:  Ahn Na Koo; Hong Jae Lee; Sung Eun Kim; Jeong Ho Chang; Chiyoung Park; Chulhee Kim; Jae Hyung Park; Sang Cheon Lee
Journal:  Chem Commun (Camb)       Date:  2008-11-12       Impact factor: 6.222

7.  Rational Design of a New Self-Codelivery System from Redox-Sensitive Camptothecin-Cytarabine Conjugate Assembly for Effectively Synergistic Anticancer Therapy.

Authors:  Wenxiu He; Xu Hu; Wei Jiang; Ruiling Liu; Di Zhang; Jing Zhang; Zhonghao Li; Yuxia Luan
Journal:  Adv Healthc Mater       Date:  2017-10-27       Impact factor: 9.933

Review 8.  Combinational strategy for high-performance cancer chemotherapy.

Authors:  Si-Yong Qin; Yin-Jia Cheng; Qi Lei; Ai-Qing Zhang; Xian-Zheng Zhang
Journal:  Biomaterials       Date:  2018-04-18       Impact factor: 12.479

9.  Codelivery of Paclitaxel and Everolimus at the Optimal Synergistic Ratio: A Promising Solution for the Treatment of Breast Cancer.

Authors:  Loujin Houdaihed; James C Evans; Christine Allen
Journal:  Mol Pharm       Date:  2018-06-14       Impact factor: 4.939

10.  Tetramethylpyrazine Enhances the Antitumor Effect of Paclitaxel by Inhibiting Angiogenesis and Inducing Apoptosis.

Authors:  Liang Zou; Xiaowei Liu; Jingjing Li; Wei Li; Lele Zhang; Jian Li; Jinming Zhang
Journal:  Front Pharmacol       Date:  2019-06-25       Impact factor: 5.810

View more
  6 in total

1.  Recent trends of bioconjugated nanomedicines through nose-to-brain delivery for neurological disorders.

Authors:  Govinda Shivaji Jadhav; Tejas Girish Agnihotri; Bichismita Sahu; Aakanchha Jain
Journal:  Drug Deliv Transl Res       Date:  2022-05-15       Impact factor: 4.617

Review 2.  Nanoparticles as Physically- and Biochemically-Tuned Drug Formulations for Cancers Therapy.

Authors:  Valentina Foglizzo; Serena Marchiò
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

3.  A pH-sensitive supramolecular nanosystem with chlorin e6 and triptolide co-delivery for chemo-photodynamic combination therapy.

Authors:  Yihan Wu; Jingjing Li; Xuemei Zhong; Jinfeng Shi; Yanfen Cheng; Chenglin He; Jiaxin Li; Liang Zou; Chaomei Fu; Meiwan Chen; Jinming Zhang; Huile Gao
Journal:  Asian J Pharm Sci       Date:  2022-01-16       Impact factor: 9.273

Review 4.  Recent Advances in Stimuli-Sensitive Amphiphilic Polymer-Paclitaxel Prodrugs.

Authors:  Man Zhou; Lijuan Wen; Cui Wang; Qiao Lei; Yongxiu Li; Xiaoqing Yi
Journal:  Front Bioeng Biotechnol       Date:  2022-04-06

Review 5.  Tetramethylpyrazine: A Review of Its Antitumor Potential and Mechanisms.

Authors:  Shaojie Yang; Shuodong Wu; Wanlin Dai; Liwei Pang; Yaofeng Xie; Tengqi Ren; Xiaolin Zhang; Shiyuan Bi; Yuting Zheng; Jingnan Wang; Yang Sun; Zhuyuan Zheng; Jing Kong
Journal:  Front Pharmacol       Date:  2021-12-16       Impact factor: 5.810

6.  Cytarabine delivered by CD44 and bone targeting redox-sensitive liposomes for treatment of acute myelogenous leukemia.

Authors:  Hao Wu; Yuan Gao; Jia Ma; Maosong Hu; Jing Xia; Shuting Bao; Yuxi Liu; Kai Feng
Journal:  Regen Biomater       Date:  2022-08-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.